Skip to main content
Press release November 9, 2026

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Orthofix Medical Inc. (OFIX)

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net sales and non-GAAP adjusted EBITDA guidance. Unless otherwise noted, pro forma results exclude the impact of the discontinued M6™ product lines. Third Quarter 2026 Highlights Total reported net sales of $207.9 million, representing an increase of 1% on a reported basis and 2% on a pro forma constant currency basis compared with the prior year period. Reported net loss of $(6.1) million and non-GAAP adjusted EBITDA of $26.0 million. Revised full-year 2026 pro forma net sales guidance to $825 million to $830 million and non-GAAP adjusted EBITDA guidance to $86 million to $88 million, reflecting third-quarter performance and the anticipated fourth quarter impact of actions to improve U.S. Spine execution, instrument set availability and asset productivity. Global Spine Fixation 1 net sales increased 1% on a reported and constant currency basis compared with the prior year period. Global Limb Reconstruction net sales increased 8% on a reported basis and 9% on a constant currency basis compared with the prior year period. Therapeutic Solutions net sales increased 4% compared with the prior year period. “Continued growth in Limb Reconstruction and Therapeutic Solutions helped offset weaker Spine performance,” said Massimo Calafiore, President and Chief Executive Officer. “In U.S. Spine, we are accelerating actions to strengthen commercial execution, improve instrument set supply and allocation, and increase asset productivity by focusing resources on our highest-performing distributor partners, products and market opportunities. Our revised guidance reflects third-quarter performance and the near-term impact of these actions, which are intended to build a stronger foundation for sustainable growth, profitability and cash generation.” 1 Spine Fixation is comprised of the Company’s Spinal Implants product category, excluding motion preservation product offerings. Financial Results Overview Third Quarter 2026 Net Sales and Financial Results The following table presents net sales by product category and reporting segment on a pro forma basis, removing the effects of the Company’s discontinued M6 product lines: Three Months Ended September 30, (Unaudited, U.S. Dollars, in millions) 2026 2025 Change Constant Currency Change Therapeutic Solutions $ 64.0 $ 61.2 4.5 % 4.5 % Spinal Implants, Biologics and Enabling Technologies* 107.4 108.6 (1.1 %) (1.1 %) Global Spine* 171.4 169.8 0.9 % 0.9 % Global Limb Reconstruction 36.4 33.6 8.5 % 9.4 % Pro forma net sales* 207.8 203.4 2.2 % 2.3 % Impact from discontinuation of M6 product lines 0.1 2.2 (96.8 %) (96.8 %) Reported net sales $ 207.9 $ 205.6 1.1 % 1.2 % * Results above for each of Spinal Implants, Biologics, and Enabling Technologies; Global Spine; and pro forma net sales exclude the impact from discontinuation of the M6 product lines. Since pro forma net sales represent a non-GAAP measure, see the reconciliation above of the Company’s pro forma net sales to its reported figures under U.S. GAAP. The Company’s reported figures under U.S. GAAP represent each of the pro forma line items discussed above plus the impact from discontinuation of the M6 product lines. For the third quarter of 2026, net sales were $207.9 million, representing an increase of 1.1% on a reported basis and 2.3% on a non-GAAP pro forma constant currency basis compared to third quarter 2025. For the third quarter of 2026, GAAP gross margins were 70.5% and were 70.7% on a non-GAAP adjusted basis. For the third quarter of 2026, reported net loss was $(6.1) million, or $(0.15) per share compared to reported net loss of $(22.8) million, or $(0.57) per share in the prior year period. Non-GAAP adjusted EBITDA was $26.0 million, or 12.5% of pro forma net sales, in the third quarter of 2026, compared to non-GAAP adjusted EBITDA of $24.6 million, or 12.1% of pro forma net sales, in the third quarter of 2025. The year-over-year increase primarily reflected continued cost discipline and resource alignment initiatives, partially offset by lower Spine revenue, unfavorable geographic mix and the related reduction in operating leverage. Liquidity Cash, cash equivalents, and restricted cash totaled $86.9 million at September 30, 2026, compared with $104.4 million at June 30, 2026. The sequential change primarily reflected working capital timing. Business Outlook Orthofix is revising its full-year 2026 net sales and adjusted EBITDA guidance. Both guidance ranges assume current foreign currency exchange rates. Net sales are now expected to range from $825 million to $830 million, compared with prior guidance of $845 million to $855 million. Non-GAAP adjusted EBITDA guidance is now expected to range from $86 million to $88 million, compared with prior guidance of $95 million to $98 million. An investor presentation for the Company’s third quarter 2026 financial results is available in the “Events & Presentations” section of the Orthofix Investor Relations website at ir.orthofix.com. Conference Call Orthofix will host a conference call today at 8:30 AM Eastern Time to discuss the Company’s financial results for the third quarter ended September 30, 2026. Interested parties may access the conference call by dialing (833) 461-5787 in the U.S., and (585) 542-9983 in all other locations, and referencing the conference ID 165515415. A webcast and replay of the conference call may be accessed in the “Events & Presentations” section of the Orthofix Investor Relations website at ir.orthofix.com. Internet Posting of Information Orthofix regularly shares important updates in the “Investors” section of its website at www.orthofix.com. The Company encourages investors and potential investors to consult the Orthofix website regularly for important information about Orthofix. About Orthofix Orthofix is a global medical technology company dedicated to advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, the Company offers a differentiated portfolio of spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies, including the 7D FLASH™ Navigation System. Orthofix’s technology-enabled solutions are designed to support surgeons across the continuum of care and improve outcomes for patients. Learn more at Orthofix.com and follow Orthofix on LinkedIn. Forward-Looking Statements This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, intentions, plans, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “positioned,” “deliver,” or “continue” or other comparable terminology. Forward-looking statements in this communication include, among other things, statements regarding the Company's business and financial outlook; expected net sales and adjusted EBITDA for the year ending December 31, 2026; ongoing and planned commercial and resource-allocation initiatives; and the anticipated effects of those initiatives on net sales, capital efficiency, growth, profitability and cash generation. Forward-looking statements are not guarantees of our future performance, are based on our current expectations and assumptions regarding our business, the economy and other future conditions, and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025, and in Part II, Item 1A under the heading Risk Factors in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Factors that could cause future results to differ from those expressed by forward-looking statements include, but are not limited to, (i) our ability to maintain operations to support our customers and patients in the near-term and to capitalize on future growth opportunities, (ii) risks associated with acceptance of surgical products and procedures by surgeons and hospitals, (iii) development and acceptance of new products or product enhancements, (iv) clinical and statistical verification of the benefits achieved via the use of our products, (v) our ability to adequately manage inventory, (vi) our ability to successfully optimize our commercial channels, (vii) our success in defending legal proceedings brought against us, and (viii) the other risks and uncertainties more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”). As a result of these various risks, our actual outcomes and results may differ materially from those expressed in these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. The Company undertakes no obligation to update, and expressly disclaims any duty to update, its forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise, except as required by law. The Company is unable to provide expectations of GAAP net income (loss), the closest comparable GAAP measures to adjusted EBITDA (which is a non-GAAP measure), on a forward-looking basis because the Company is unable to predict, without unreasonable efforts, the ultimate outcome of matters (including acquisition-related expenses, accounting fair value adjustments, and other such items) that will determine the quantitative amount of the items excluded in calculating adjusted EBITDA, which items are further described in the reconciliation tables and related descriptions below. These items are uncertain, depend on various factors, and could be material to the Company’s results computed in accordance with GAAP. ORTHOFIX MEDICAL INC. Condensed Consolidated Statements of Operations Three Months Ended Nine Months Ended September 30, September 30, (Unaudited, U.S. Dollars, in thousands, except share and per share data) 2026 2025 2026 2025 Net sales $ 207,862 $ 205,634 $ 615,503 $ 602,401 Cost of sales 61,316 57,111 179,704 192,726 Gross profit 146,546 148,523 435,799 409,675 Sales, general, and administrative 125,330 148,102 398,271 417,576 Research and development 15,277 14,774 46,541 50,474 Acquisition-related amortization, impairment, and remeasurement 4,394 2,693 12,012 23,547 Operating income (loss) 1,545 (17,046 ) (21,025 ) (81,922 ) Interest expense, net (5,889 ) (4,681 ) (17,638 ) (13,137 ) Other income (expense), net (904 ) (535 ) (2,416 ) 6,441 Loss before income taxes (5,248 ) (22,262 ) (41,079 ) (88,618 ) Income tax expense (826 ) (533 ) (1,701 ) (1,352 ) Net loss $ (6,074 ) $ (22,795 ) $ (42,780 ) $ (89,970 ) Net loss per common share: Basic $ (0.15 ) $ (0.57 ) $ (1.05 ) $ (2.28 ) Diluted (0.15 ) (0.57 ) (1.05 ) (2.28 ) Weighted average number of common shares (in millions): Basic 41.2 39.8 40.8 39.5 Diluted 41.2 39.8 40.8 39.5 ORTHOFIX MEDICAL INC. Condensed Consolidated Balance Sheets (U.S. Dollars, in thousands, except par value data) September 30, 2026 December 31, 2025 (Unaudited) Assets Current assets Cash and cash equivalents $ 86,322 $ 82,025 Restricted Cash 598 3,090 Accounts receivable, net of allowances of $11,583 and $8,308, respectively 131,719 135,746 Inventories 190,357 172,319 Prepaid expenses and other current assets 21,791 23,667 Total current assets 430,787 416,847 Property, plant, and equipment, net 133,388 129,399 Intangible assets, net 62,904 72,765 Goodwill 194,934 194,934 Other long-term assets 33,748 36,702 Total assets $ 855,761 $ 850,647 Liabilities and shareholders’ equity Current liabilities Accounts payable $ 58,032 $ 58,392 Current portion of finance lease liability 136 837 Other current liabilities 80,217 111,253 Total current liabilities 138,385 170,482 Long-term debt 221,847 157,391 Long-term portion of finance lease liability 12,868 17,060 Other long-term liabilities 53,094 55,677 Total liabilities 426,194 400,610 Contingencies Shareholders’ equity Common shares $0.10 par value; 100,000 shares authorized; 40,749 and 39,834 issued and outstanding as of September 30, 2026, and December 31, 2025, respectively 4,075 3,983 Additional paid-in capital 837,165 813,769 Accumulated deficit (411,113 ) (368,333 ) Accumulated other comprehensive income (loss) (560 ) 618 Total shareholders’ equity 429,567 450,037 Total liabilities and shareholders’ equity $ 855,761 $ 850,647 ORTHOFIX MEDICAL INC. Non-GAAP Financial Measures The following tables present reconciliations of various financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), to various non-GAAP financial measures that exclude (or in the case of free cash flow, include) items specified in the tables. The GAAP measures shown in the tables below represent the most comparable GAAP measure to the applicable non-GAAP measure(s) shown in the table. For further information regarding the nature of these exclusions, why the Company believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company’s current report on Form 8-K regarding this press release filed today with the SEC available on the SEC’s website at www.sec.gov and on the “Investors” page of the Company’s website at www.orthofix.com. The Company’s non-GAAP financial measures for the three and nine months ended September 30, 2026, and 2025, have been adjusted to eliminate the financial effects of the Company’s decision to discontinue its M6 product lines. Adjusted Gross Profit and Adjusted Gross Margin Three Months Ended Nine Months Ended September 30, September 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Gross profit $ 146,546 $ 148,523 $ 435,799 $ 409,675 Share-based compensation and long-term incentive plan expense 236 368 1,029 1,297 SeaSpine merger-related costs 116 (438 ) (187 ) 4,503 Gross profit and impairments related to M6 product lines (106 ) (1,989 ) (621 ) 9,176 Strategic investments — 1 — 57 Amortization/depreciation of acquired long-lived assets 109 276 394 940 Employee transition costs 13 — 606 — Adjusted gross profit $ 146,914 $ 146,741 $ 437,020 $ 425,648 Adjusted gross margin as a percentage of reported net sales 70.7 % 71.4 % 71.0 % 70.7 % Adjusted gross margin as a percentage of pro forma net sales 70.7 % 72.1 % 71.0 % 71.7 % Adjusted EBITDA Three Months Ended Nine Months Ended September 30, September 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Net loss $ (6,074 ) $ (22,795 ) $ (42,780 ) $ (89,970 ) Income tax expense 826 533 1,701 1,352 Interest expense, net 5,889 4,681 17,638 13,137 Depreciation and amortization 13,172 12,941 39,938 64,243 Share-based compensation and long-term incentive plan expense 6,969 7,181 21,552 21,474 Foreign exchange impact 744 571 2,390 (3,224 ) SeaSpine merger-related costs 412 126 915 6,142 Operating losses and impairments related to M6 product lines 464 6 1,802 15,485 Strategic investments 509 227 2,093 4,094 Acquisition-related fair value adjustments 1,396 (427 ) 3,014 (1,800 ) Interest and loss on investments — (10 ) (16 ) (41 ) Litigation and investigation costs 301 21,548 5,402 28,619 Employee retention credit — — (951 ) (2,854 ) Employee transition costs 1,428 — 3,170 — Adjusted EBITDA $ 26,036 $ 24,582 $ 55,868 $ 56,657 Adjusted EBITDA as a percentage of reported net sales 12.5 % 12.0 % 9.1 % 9.4 % Adjusted EBITDA as a percentage of pro forma net sales 12.5 % 12.1 % 9.1 % 9.5 % Adjusted Net Income Three Months Ended Nine Months Ended September 30, September 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Net loss $ (6,074 ) $ (22,795 ) $ (42,780 ) $ (89,970 ) Share-based compensation and long-term incentive plan expense 6,969 7,181 21,552 21,474 Foreign exchange impact 744 571 2,390 (3,224 ) SeaSpine merger-related costs 696 151 1,287 9,411 Operating (income) losses and impairments related to M6 product lines 466 (438 ) 1,940 35,945 Strategic investments 511 235 2,101 4,142 Acquisition-related fair value adjustments 1,396 (427 ) 3,014 (1,800 ) Amortization/depreciation of acquired long-lived assets 3,107 3,396 9,392 12,251 Litigation and investigation costs 301 21,548 5,402 28,619 Interest and loss on investments — (10 ) (16 ) (41 ) Employee retention credit — — (1,135 ) (3,616 ) Employee transition costs 1,428 — 3,170 — Long-term income tax rate adjustment (2,078 ) (2,252 ) (544 ) (2,720 ) Adjusted net income $ 7,466 $ 7,160 $ 5,773 $ 10,471 Cash Flow and Free Cash Flow Nine Months Ended September 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 Net cash provided by (used in) operating activities $ (23,471 ) $ 5,650 Net cash used in investing activities (37,664 ) (23,727 ) Net cash provided by (used in) financing activities 63,228 (3,163 ) Effect of exchange rate changes on cash (288 ) 1,448 Net change in cash, cash equivalents, and restricted cash $ 1,805 $ (19,792 ) Nine Months Ended September 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 Net cash provided by (used in) operating activities $ (23,471 ) $ 5,650 Capital expenditures (37,810 ) (23,749 ) Free cash flow $ (61,281 ) $ (18,099 ) Reconciliation of Non-GAAP Financial Measures to Reported Operating Expenses Three Months Ended Nine Months Ended September 30, September 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Sales, general, and administrative $ 125,330 $ 148,102 $ 398,271 $ 417,576 Reconciling items impacting sales, general, and administrative: SeaSpine merger-related costs (509 ) (538 ) (1,265 ) (4,680 ) Operating losses and impairments related to M6 product lines (211 ) (954 ) (1,668 ) (8,314 ) Strategic investments (510 ) (199 ) (2,091 ) (1,940 ) Amortization/depreciation of acquired long-lived assets — — — (60 ) Litigation and investigation costs (301 ) (21,548 ) (5,402 ) (28,169 ) Employee transition costs (1,235 ) — (2,383 ) — Sales, general, and administrative expense, as adjusted $ 122,564 $ 124,863 $ 385,462 $ 374,413 As a percentage of reported net sales 59.0 % 60.7 % 62.6 % 62.2 % As a percentage of pro forma net sales 59.0 % 61.4 % 62.7 % 63.1 % Three Months Ended Nine Months Ended September 30, September 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Research and development expense, as reported $ 15,277 $ 14,774 $ 46,541 $ 50,474 Reconciling items impacting research and development: SeaSpine merger-related costs (70 ) (50 ) (209 ) (228 ) Operating losses and impairments related to M6 product lines (390 ) (582 ) (1,049 ) (4,305 ) Strategic investments (2 ) (34 ) (10 ) (2,144 ) Litigation and investigation costs — — — (450 ) Employee transition costs (182 ) — (182 ) — Research and development expense, as adjusted $ 14,633 $ 14,108 $ 45,091 $ 43,347 As a percentage of reported net sales 7.0 % 6.9 % 7.3 % 7.2 % As a percentage of pro forma net sales 7.0 % 6.9 % 7.3 % 7.3 % Reconciliations of Non-GAAP Financial Measures to Reported Non-Operating (Income) Expense Three Months Ended Nine Months Ended September 30, September 30, (Unaudited, U.S. Dollars, in thousands) 2026 2025 2026 2025 Non-operating (income) expense $ 6,793 $ 5,216 $ 20,054 $ 6,696 Reconciling items impacting non-operating expense: Non-operating (income) losses and impairments related to M6 product lines 30 (16 ) 156 (54 ) Foreign exchange impact (744 ) (571 ) (2,390 ) 3,224 Interest and loss on investments — 10 16 41 Employee retention credit — — 1,135 3,616 Non-operating expense, as adjusted $ 6,079 $ 4,639 $ 18,971 $ 13,523 As a percentage of reported net sales 2.9 % 2.3 % 3.1 % 2.2 % As a percentage of pro forma net sales 2.9 % 2.3 % 3.1 % 2.3 % Company Contact Investors and Media Julie Dewey, IRC Chief Investor Relations & Communications Officer JulieDewey@Orthofix.com +1 209.613.6945 Source: Orthofix Medical Inc.
View original release